Home > Publications database > Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study > print

001     144611
005     20240229112631.0
024 7 _ |a 10.3389/fimmu.2019.01848
|2 doi
024 7 _ |a WOS:000479149400001
|2 WOS
024 7 _ |a altmetric:65168580
|2 altmetric
037 _ _ |a DKFZ-2019-02053
082 _ _ |a 610
100 1 _ |a Marchini, Antonio
|0 P:(DE-He78)2c1968abb9781c0328997892355fa74c
|b 0
|e First author
|u dkfz
245 _ _ |a Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
260 _ _ |a Lausanne
|c 2019
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1566568299_407
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 316 - Infections and cancer (POF3-316)
|0 G:(DE-HGF)POF3-316
|c POF3-316
|f POF III
|x 0
588 _ _ |a Dataset connected to Web of Science, Web of Science, , CrossRef
700 1 _ |a Daeffler, Laurent
|b 1
700 1 _ |a Pozdeev, Vitaly I.
|b 2
700 1 _ |a Angelova, Assia
|0 P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0
|b 3
|u dkfz
700 1 _ |a Rommelaere, Jean
|0 P:(DE-He78)2d7958ea507b0b738619074b38ec6d54
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.3389/fimmu.2019.01848
|g Vol. 10, p. 1848
|0 PERI:(DE-600)2606827-8
|p 1848
|t Frontiers in immunology
|v 10
|y 2019
|x 1664-3224
909 C O |o oai:inrepo02.dkfz.de:144611
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2c1968abb9781c0328997892355fa74c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)2d7958ea507b0b738619074b38ec6d54
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|2 G:(DE-HGF)POF3-300
|v Infections and cancer
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2017
920 1 _ |0 I:(DE-He78)F010-20160331
|k F010
|l Tumorvirologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F010-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21